Altasomil
Altasomil Uses, Dosage, Side Effects, Food Interaction and all others data.
Altasomil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Altasomil activates glutamatergic circuits while inhibiting GABA.
Altasomil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. Altasomil is not indicated for complaints of lack of energy or fatigue; but it appears to be very helpful for some patients. Also, it has been used in the treatment of hypersomnia, a disorder in which patients lack the capacity for meaningful sleep and may require ten or more hours per day. Recent studies have have found that modafinil may help recovering cocaine addicts fight their addiction.
| Trade Name | Altasomil |
| Availability | Prescription only |
| Generic | Modafinil |
| Modafinil Other Names | Modafinil, Modafinilo, Modafinilum |
| Related Drugs | Adderall, methylphenidate, Concerta, Ritalin, dextroamphetamine, amphetamine / dextroamphetamine, armodafinil, Provigil, Nuvigil, Sunosi |
| Type | |
| Formula | C15H15NO2S |
| Weight | Average: 273.35 Monoisotopic: 273.082349419 |
| Protein binding | 60% |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Slovenia |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Altasomil is a stimulant used to improve wakefulness in patients with sleep apnea, narcolepsy, or shift work disorder.
To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
Altasomil is also used to associated treatment for these conditions: Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
How Altasomil works
The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Altasomil activates glutamatergic circuits while inhibiting GABA. Altasomil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Altasomil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors.
Food Interaction
- Take with or without food. The absorption is unaffected by food.
[Minor] Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability.
According to the product labeling, modafinil's absorption may be delayed by approximately one hour if taken with food.
Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.
Altasomil Hypertension interaction
[Major] CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.
Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.
All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.
Altasomil Drug Interaction
Minor: amphetamine / dextroamphetamine, amphetamine / dextroamphetamine, lisdexamfetamine, lisdexamfetamine, alprazolam, alprazolamUnknown: duloxetine, duloxetine, omega-3 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, pregabalin, pregabalin, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol, cetirizine, cetirizine
Altasomil Disease Interaction
Major: cardiac disease, hypertension, liver disease, psychiatric disordersModerate: bipolar disorders, psychotic disorders, renal dysfunction, seizure disorders, cardiovascular
Volume of Distribution
- 0.9 L/kg
Elimination Route
Rapid following oral administration.
Half Life
23-215 hours
Elimination Route
The major route of elimination is metabolism (~90%), primarily by the liver, with subsequent renal elimination of the metabolites.
Innovators Monograph
You find simplified version here Altasomil
